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AbstrACt
Introduction Though Senegal has one of the highest 
estimated prevalence rates of chronic hepatitis B virus 
(HBV) infection worldwide, epidemiological data in the 
general population are lacking and consequences of 
the infection remain undocumented. The ANRS-12356 
AmBASS study aims at evaluating the health and 
socioeconomic burden of chronic HBV infection at the 
individual, household and population level. Its specific 
objectives are (1) to document the epidemiology of chronic 
HBV infection, including prevalence and risk factors; (2) to 
assess the acceptability of home-based testing and first 
clinic visit; (3) to investigate the repercussions of chronic 
HBV infection on living conditions; and (4) to estimate 
the public health impact of chronic HBV infection at the 
population level and the feasibility of a decentralised 
model of HBV test and treat.
Methods and analysis This multidisciplinary cross-
sectional survey includes a twofold data collection: (1) 
home-based screening using dried blood spot (DBS) 
sampling and collection of sociodemographic, economic 
and behavioural data, and (2) additional clinical and 
biological data collection in chronic HBV carriers at the first 
clinic visit. The prevalence of chronic HBV infection will be 
estimated in the general population and in key subgroups. 
Risk factors for HBV acquisition in children will be explored 
using case-control analysis. HBV burden will be assessed 
through comparisons of health and economic outcomes 
between households affected by the disease versus non-
affected households. Last, an economic evaluation will 
assess costs and health benefits of scaling-up HBV care.
Ethics and dissemination This study was approved by 
the Senegalese National Ethical Committee for Research 
in Health, and received authorisation from the Senegalese 
Ministry of Health and the French Commission on 
Information Technology and Liberties (Senegalese Protocol 
Number: SEN17/15). The study results will be presented 
in peer-review journals, international conferences and 
at a workshop with national stakeholders in order to 
contribute to the design of programmes to address the 
HBV pandemic.
trial registration number NCT03215732; Pre-results.
IntroduCtIon
Epidemiology of hepatitis b in sub-saharan 
Africa: a significant burden
In 2015, an estimated 257 million people 
were chronically infected with hepatitis 
B virus (HBV) worldwide, and chronic 
HBV infection was responsible for 887 000 
deaths.1 With 60 million people living with 
chronic HBV infection and an estimated 
prevalence of 6.1% in the adult population, 
Africa is the second most affected region in 
the world after Asia, a burden that has long 
been neglected.2 HBV prevalence is particu-
larly high in West Africa with estimated rates 
between 6% and 16% in the adult popula-
tion, depending on the country.3 4 In this 
strengths and limitations of this study
 ► The AmBASS study is a cross-sectional survey, 
which combines biological, clinical and socioeco-
nomic data collection to assess both health and 
socioeconomic burden of the hepatitis B virus (HBV) 
infection at the individual, household and population 
level.
 ► After home-based pretest counselling and HBV test-
ing using dried blood spots, participants are invited 
to visit their local healthcare facilities to get their re-
sults and benefit from post-test counselling.
 ► Additional clinical and biological data are collected 
in healthcare facilities among participants diag-
nosed with chronic HBV infection to provide an es-
timation of HBV treatment needs and to document 
the economic feasibility of expanding access to HBV 
testing and treatment.
 ► Important work migrations in the study area may 
introduce bias in the population sample.
 ► The Niakhar area may not be representative of the 
whole country of Senegal or of other countries in 
West Africa.
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region, most HBV infections occur in early childhood, 
through mother-to-child transmission (MTCT)—that is, 
vertical transmission—and contact with other infected 
young children—that is, horizontal transmission.5–8 
Primary HBV infection remains most often asymptom-
atic, but can lead to chronic infection in up to 90% of 
cases when infection occurs at less than 6 months of age 
and in 20%–60% of cases in children infected between 
the ages of 6 months and 5 years (vs only 5% when infec-
tion occurs at adulthood).9 Left untreated, 15%–40% 
of chronic HBV carriers will develop severe complica-
tions, including cirrhosis, hepatic failure and hepato-
cellular carcinoma (HCC)—the most common form of 
liver cancer—which can lead to death.10 In sub-Saharan 
Africa, liver cancer is among the cancers with the highest 
mortality, with approximately 200 000 deaths each year, 
and a mean survival estimated at only a few months after 
diagnosis.11 
Hepatitis b prevention and treatment: major challenges to 
address the needs
The cornerstone of preventing HBV is active immunisa-
tion.12 An effective vaccine against HBV has been avail-
able since 1981. It has been included in the Expanded 
Programmes on Immunisation (EPI) of most African 
countries over the past 15 years, generally in combination 
with other vaccines administrated beginning 6 weeks after 
birth.13 However, a first administration of HBV vaccine at 
birth (within the first 24 hours of life) is essential to effec-
tively reduce MTCT of the virus as recommended by the 
WHO in highly endemic areas since 2009.14–16 The imple-
mentation of this key intervention remains a challenge in 
sub-Saharan Africa, with a significant number of women 
still giving birth at home. Furthermore, as of 2015, the 
birth dose was only included in a few EPI of sub-Saharan 
African countries resulting in an estimated 10% of birth 
dose coverage in this region.1
Effective antiviral treatments can control HBV replica-
tion, prevent disease-associated complications and signifi-
cantly reduce HBV-related mortality.14 These lifelong 
treatments include interferon, pegylated interferon, and 
six nucleos(t)ide analogues (NAs) (lamivudine, telbivu-
dine, emtricitabine, entecavir, adefovir and tenofovir).14 
The WHO recommends the use of NAs with a high barrier 
to drug resistance (ie, tenofovir and entecavir in adults, and 
entecavir in children aged 2–11 years) in individuals with 
cirrhosis (defined as an obvious clinical diagnosis and/or 
AST to Platelet Ratio Index (APRI) score >2 regardless of 
ALT/AST (ALT, alanine transaminase/aminotransferase; 
AST, aspartate transaminase) levels, HBeAg status and 
HBV DNA levels), and in individuals who are 30 years of 
age and above with abnormal ALT/AST levels and high 
viral replication (HBV DNA >20 000 IU/mL regardless of 
HBeAg status).12
However, access to affordable testing and treatment 
for people living with chronic HBV infection remains 
suboptimal in sub-Saharan Africa.17 18 According to the 
WHO, few people with chronic HBV infection have been 
diagnosed (ie, 9% worldwide but much less in sub-Sa-
haran Africa) and only a small fraction (estimated at 8% 
in 2015) of those diagnosed can access treatment.1
Hepatitis b socioeconomic burden
The literature on the socioeconomic burden of hepatitis 
B and on its impacts on the living conditions of infected 
people remains scarce in high endemic areas.19–22 Quality 
of life with chronic hepatitis B has been documented in 
several studies, mostly conducted in Asia,23–30 showing 
impaired quality of life in chronic HBV carriers compared 
with the general population. However, only one study in 
sub-Saharan Africa—in Uganda—assessed the relation-
ship between HBV infection and poverty and showed 
a negative correlation between wealth index and HBV 
infection.31
In contrast, there is a vast literature addressing the 
economic value of HBV treatments in the setting of 
high-resource countries,32–39 but practically no cost-effec-
tiveness analysis in sub-Saharan Africa, with the exception 
of a recent study on the cost-effectiveness of communi-
ty-based HBV screening and treatment in Gambia.40 A 
few studies have also been conducted on the cost-effec-
tiveness of HBV vaccine in low and middle income coun-
tries.41–43 However, there is a lack of economic evaluations 
on the public health impacts of hepatitis B as well as on 
the public health benefits and budget implications of scal-
ing-up HBV testing and treatment in sub-Saharan Africa.
Hepatitis b in senegal
Hepatitis B is hyper endemic in Senegal. It is estimated 
that 85% of the population has been infected with HBV,44 
and according to a 2015 systematic review, the preva-
lence of chronic HBV infection reaches 11% or more.4 
However, currently available prevalence data rely on 
cross-sectional studies conducted within at-risk popula-
tions (drug users, HIV coinfected individuals) or specific 
subpopulations (eg, military, blood donors)45–52 but no 
study has been carried out in the general population. In 
addition, as 60% of people may have been infected with 
HBV before turning 5 years old,53 HBV-related morbidity 
and mortality is expected to remain high. According 
to the WHO, liver cancer is the second cancer with the 
highest incidence and mortality rates in Senegalese men, 
and the third in Senegalese women.13 Despite this critical 
situation, the burden and impacts on living conditions of 
chronic HBV infection in the general population of the 
country remain undocumented.
Key actors in the fight against HBV in Senegal include 
the national hepatitis programme set up in 1998 by the 
Senegalese government,39 the Senegalese Society of 
Gastro-Enterology and Hepatology (SOSEGH) founded 
in 2007 to gather hepatitis experts in the country, and 
the HBV patient association ‘Saafara Hépatites Sénégal’ 
which was established in 2011 to encourage HBV testing 
and outreach to the general population. Despite the 
implementation of several HBV vaccine trials in Senegal 
(including in the Niakhar area) in the late seventies, 
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the national EPI only introduced systematic vaccina-
tion against HBV in 2004 with a three dose schedule 
(pentavalents 1, 2 and 3 to be administered at 6, 10 and 14 
weeks, respectively54). The recent objective of the health 
authorities has been to enhance HBV screening in preg-
nant women and to implement vaccination in newborns 
(birth dose) which is part of the country’s EPI since 
February 2016.13 According to estimates of the national 
hepatitis programme, HBV vaccine birth dose coverage 
had reached 82% in December 2017.13
In contrast, both HBV testing in adults and global access 
to HBV treatment remain a very important challenge. A 
working group was launched in 2016 to develop national 
guidelines to promote access to HBV treatment at the 
decentralised level of the healthcare system. However, 
these guidelines are yet to be officially adopted, and access 
to antiviral treatment is only available in major hospi-
tals located in the country’s two main cities (Dakar and 
St-Louis). Moreover, with the exception of HBV special-
ists, the majority of caregivers, including physicians, still 
have incomplete knowledge of hepatitis B screening and 
care, including treatment initiation and follow-up.55
objECtIvEs
The overall objective of the study is to assess both the 
health and socioeconomic burden of chronic HBV infec-
tion at the individual, household and population level.
specific objectives
1. To document the epidemiology of HBV infection in 
the Niakhar area general population including (i) es-
timation of the prevalence of chronic HBV infection 
in the whole population and in different subgroups 
according to age and gender and (ii) identification of 
behavioural and environmental risk factors of HBV ac-
quisition in children.
2. To assess the acceptability of home-based HBV testing 
and first clinic visit.
3. To investigate the consequences of chronic HBV infec-
tion on living conditions of infected individuals and 
their households.
4. To estimate the public health impact of chronic HBV 
infection at the population level and feasibility of a de-
centralised model of HBV test and treat.
MEtHods And AnAlysIs
study design
The ANRS 12356 AmBASS study is a multidisciplinary 
cross-sectional survey which is conducted within a repre-
sentative sample of the population living in the Niakhar 
area with a two-level data collection: (1) at home for 
HBV screening using dried blood spot (DBS) sampling 
and collection of sociodemographic, economic and 
behavioural data using face-to-face questionnaires, and 
(2) in healthcare facilities for test results delivery and post-
test counselling to all participants as well as additional 
clinical and biological data collection in chronic HBV 
patients. The study also includes a preliminary phase to 
inform national and regional health authorities as well as 
local community leaders about the research and its public 
health challenges, to assess the local healthcare workers’ 
(HCW) knowledge in the field of prevention, care and 
treatment of chronic HBV infection, to train the study 
team and HCW working in the healthcare facilities of the 
study area and to conduct a pilot survey (figure 1). This 
preliminary phase took place between April 2017 and 
August 2018. The main data collection started in October 
2018, and is expected to end mid-2019.
Study setting: the Niakhar Health and Demographic Surveillance 
System
The survey is conducted in the area of the Niakhar 
Health and Demographic Surveillance System (HDSS), 
the oldest HDSS of Senegal, and one of the oldest in 
Western Africa. Created in 1962, the Niakhar HDSS is 
located 135 km East of Dakar, covers 203 km2 and a popu-
lation of 44 854 individuals (January 2018 census) distrib-
uted across 30 villages.56 The Niakhar HDSS has local 
health and demographic surveillance infrastructures 
(Niakhar station) including offices, information tech-
nology and basic laboratory equipment, vehicles and staff 
on site, mainly interviewers and technicians trained in 
questionnaire administration and collection of biological 
data.57 The population of the Niakhar area is regularly 
followed-up, and events such as migrations, marriages, 
pregnancies or death are recorded in the HDSS database. 
The area of Niakhar counts four local public clinics, with 
the support of two healthcare centres in Niakhar and 
Fatick districts (referral centres at the district level) and a 
regional hospital in Fatick, located 15 km from Niakhar.
Study population
The study population includes all individuals living in 
randomly selected households in the Niakhar area for 
at least 6 months during the year (eg, seasonal workers 
Figure 1 General design of the ANRS 12356 AmBASS 
survey. DBS,  dried blood spot;  HBV, hepatitis B virus; HCW, 
healthcare workers; *Only for chronic HBV carriers.
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or individuals studying outside the Niakhar area are 
also included),56 aged at least 6 months (for feasibility 
purposes) and who have given informed consent to 
participate to the study (for children under 15 years old, 
parental consent is required). There is no specific exclu-
sion criterion at the household level. At the individual 
level, exclusion criteria are as follows: being an adult 
unable to sign informed consent, or being a child whose 
parent or legal guardian is not present in the household 
at the time of the survey.
Sample size calculation
The calculation of the sample size was based on the 
following standard formula used for prevalence surveys58 
: N = (Z1−α)
2 (P (1 – P)/D2), where Z1-α corresponds to 
the value of the Z statistic for the chosen level of confi-
dence (eg, 1.96 for 95% CIs), P is the estimated preva-
lence based on data from the literature and D is the 
required precision (generally set between 3% and 5%), 
which corresponds to half the width of the 95% CI for the 
estimated prevalence. The sample size was determined to 
provide an estimated prevalence of chronic HBV infec-
tion in the general population of the area with 1.2% 
precision, and an estimated prevalence of chronic HBV 
infection in women of childbearing age (15–49 years 
old) and in the main age groups (<15 years old, 15 to 35 
years old, and >35 years old) with 3% precision. Based 
on available data in the literature on HBV prevalence in 
Senegal,4 20 52 we hypothesised a minimum HBV preva-
lence of 10%, and a maximum prevalence of 17%. On 
the basis of response rates observed in previous sociode-
mographic and medical surveys conducted by the HDSS 
team in the area, we hypothesised a 90% participation 
rate in the AMBASS survey. In addition, a 3% loss rate is 
expected for DBS (corresponding to unexploitable DBS 
samples, for which HBV screening will not be possible). 
These hypotheses, together with the expected precision 
in estimated prevalence rates, resulted in a target sample 
size of 3200 participants.
Selection of participating households
Sampling relies on a two-stage stratified design. The 
sampling frame is made of 26 villages located in the 
Niakhar area, which corresponds to all villages in the 
area with the exception of four villages due to their very 
low participation rates in previous surveys including 
blood tests. The households included in the pilot survey 
were excluded from the study sampling frame. Villages 
were then classified according to their infrastructures 
and equipment into rural villages or semiurban villages 
(stratum variable).56 Participating villages were selected at 
the first stage. The three semiurban villages and a random 
sample of nine rural villages (39%) drawn with simple 
random sampling were selected. All households listed in 
the 12 participating villages constituted the second stage 
of the sampling. Given that the average size of a house-
hold is 11 individuals in the Niakhar area, the number 
of households to select using simple random sampling 
was estimated at 291. Thirty-two additional households 
were randomly selected (complementary list) in order to 
take into account potential refusals to participate in the 
survey. Randomisation was performed by the study statis-
tician before data collection.
study procedures and data collection tools
Preliminary phase
The preliminary study phase (April 2017–August 2018) 
includes preparatory workshops with local and national 
health authorities, meetings with village leaders to 
present the study and obtain prior agreement to conduct 
the research in the community, and training of the study 
team and local HCW. Information and training needs 
about hepatitis B screening, prevention and care in HCW 
were first assessed through a preliminary survey. Care-
givers in the Niakhar area were then trained in HBV 
pretest and post-test counselling, with support from the 
Saafara Hépatites Sénégal patients-centred association 
that plays a key role in public awareness. In July 2018, an 
advanced training in HBV care management took place 
at the Fatick regional hospital, with the participation of 
the SOSEGH president, Pr Pape Saliou Mbaye. In addi-
tion, a pilot survey was conducted in October–November 
2017 among 10 households (102 participants) living in 
two different villages of the Niakhar area in order to vali-
date standard operating procedures and data collection 
tools.
First level: home-based HBV testing and data collection
The cross-sectional survey includes two levels of data 
collection corresponding to two successive steps (table 1). 
First, data are collected at home and HBV testing is 
offered to all eligible household members in randomised 
households. After the authorisation to enter the conces-
sion is obtained from the head of household, interviewers 
present the survey objectives and benefits/risks individ-
ually to each member of the household aged at least 18 
years and to children in the presence of their parents or 
legal guardian. Then, professional nurses trained in study 
procedures perform HBV testing using DBS in all individ-
uals and their children willing to participate. This rapid 
and simple technique requires a few drops of blood from 
a finger stick, which are placed on the five preprinted 
circles of a Whatman 903 Protein saver card. This proce-
dure is in line with the latest WHO recommendations 
that a single assay with reactive HBsAg is compatible 
with chronic HBV infection in areas where the HBsAg 
seroprevalence is above 0.4%, and that DBS sampling 
may be used for HBsAg in settings where venous blood 
sampling is not feasible and rapid diagnostic tests are not 
available.59
Right after DBS collection, the interviewer adminis-
ters face-to-face questionnaires to all participants born 
before 1 September 2003 (considered as ‘adults’). This 
questionnaire focuses on the economic situation, HBV 
screening and liver disease history, perceived health and 
quality of life, as well as medical conditions, healthcare 
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consumption and expenditures (table 2). For partici-
pants born after 1 September 2003 (‘children’), a specific 
questionnaire is completed by the participant’s parent 
or legal guardian. This questionnaire documents health 
condition, vaccination records and risk factors (table 3). 
Finally, a questionnaire describing the main characteris-
tics of the household (composition, agricultural produc-
tion, assets, food security and housing conditions) is also 
administered to the head of the household (table 4).
All DBS are transported to the Niakhar station labora-
tory where they are dried, then frozen at −20°C before 
being transferred for analysis to the Institut de Recherche 
en Santé, de Surveillance Épidémiologique et de Formation 
(IRESSEF). HBV biomarkers are measured using chemo-
luminescence microparticle immunoassay (Abbott 
Diagnostics, Sligo, Ireland). Study participants are invited 
to get their HBV test results and receive post-test counsel-
ling in their local healthcare facility.
Second level: healthcare facility-based HBV test results and 
additional data collection among chronic HBV carriers
HBV testing results are delivered at the local healthcare 
facilities by the local HCW with the support of the clin-
ical research team composed of a referral physician and 
two nurses, and of the HBV patients association Saafara 
Hépatites Sénégal. Participants are provided with indi-
vidual or family-based postdiagnosis HBV counselling, 
according to their preference. Individuals receive infor-
mation on hepatitis B transmission routes and preven-
tion measures including, but not limited to, MTCT, 
Table 1 Schedule of the ANRS 12356 AmBASS survey
Home Local healthcare facility
Preinclusion Screening
Test results
First clinic visit
Chronic HBV follow-up
Second clinic visit
Information X
Consent X
HBV counselling X X* X*
Clinical examination X*
Treatment eligibility X*
Referral to the hospital X*
Biological samples
  Dried blood spots X
  Venous blood X*
Biological examinations
  HBsAg X
  Anti-HBs X†
  Anti-HBc X
  HBeAg X*
  Anti-HBe X*
  HBV DNA (viral load) X*
  Anti-HIV X*
  Antihepatitis D Virus X*
  AST/ALT X*
  Prothrombin time X*
  Full blood count X*
  Platelets X*
Face-to-face questionnaires
  Individual questionnaire X
  Household questionnaire X
  Clinical questionnaire X*
*Only for HBV chronic carriers.
†Only for participants born after 1 September 2003.
Anti-HBc, hepatitis B core antibodies; Anti-HBe, antibody to the hepatitis B e-antigen; Anti-HBs, antibody to the hepatitis B surface 
antigen; AST/ALT ,  concentration ratio between the aspartate transaminase (AST), and the alanine transaminase/aminotransferase (ALT) 
enzymes; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus. 
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horizontal transmission among children and the impor-
tance of immunisation. Additional data are collected by 
the physician among chronic HBV carriers after post-
test counselling. Participants identified as chronic HBV 
patients undergo additional clinical and biological exam-
inations—including venous blood sampling—in order to 
assess the stage of liver disease and treatment eligibility. 
As for DBS, blood samples are transported, frozen and 
stored at the Niakhar station laboratory before being 
transferred to the IRESSEF laboratory where they are 
analysed. Clinical data collected using a face-to-face ques-
tionnaire include medical and family history, clinical 
symptoms of liver disease and risk factors of disease evolu-
tion (table 5). People are invited to come back to the 
facility to obtain the results of the additional biological 
tests. During this second clinical visit, which is also carried 
out by the team physician, a monitoring scheme and a 
reference at the Fatick hospital is offered depending on 
the stage of the infection.
study outcomes
Main outcome
The main study outcome is the prevalence of chronic 
HBV infection in the general population of the Niakhar 
area, defined by positive HBsAg detected in DBS samples 
collected during home visits. Drawing from a previous 
study60 and results of the pilot study, adjusted cut-off 
values of 1 (for negativity) and 1.5 (for positivity) were 
identified to define HBsAg status. For HBsAg  values 
between 1 and 1.5 IU/mL, a second measure of HBsAg 
was performed using venous blood sampling collected 
in the healthcare facility when HBV testing results were 
delivered.
Table 2 Adult questionnaire (participants born before 1 September 2003)
Main theme Specific themes
General information Gender, date of birth, marital status, number of children, residence status, migration for work or studies 
during the past year (duration of the absence and location)
Economic activity Participation to the household’s agricultural work (main or secondary activity, time worked), paid farm 
work (income), independent agricultural work (crop, area, income), other economic activities (type, status, 
time worked, income), other status (retiredretired, unemployed, disability, student)
Health and quality of life Impact of health condition on working productivity and on daily activities, health-related quality of life (SF-
12)63, fatigue (current, history, impact), disability
Maternal health* Full-term pregnancy (number, history of C-section), current pregnancy, prenatal consultations, last delivery 
(date, setting, assistance)
HBV screening and liver 
disease
Liver disease (knowledge, family history), knowledge of hepatitis B (organ affected, known routes of 
transmission), vaccine (knowledge, perceived efficacy and safety), history of HBV screening (health record, 
circumstances, date, result, treatment)
Healthcare utilisation and 
expenditures
Hospitalisation in the past 12 months, episodes of illness in the past 3 months (impact on work and daily 
activities, symptoms, medical attention, self-medication), health insurance (type, members, contribution, 
coverage), healthcare utilisation and expenditures in the past 3 months (out-of-pocket and identity of the 
payer for medication, consultation, medical examinations, hospitalisation), transport costs, Senegalese 
indigent status or certificate for subsidised care (heard of, ever applied to, date, result, amount)
*Only for women of childbearing age (15–49 years old).
HBV, hepatitis B virus.
Table 3 Child questionnaire (participants born after 1 September 2003)
Main theme Specific themes
General 
information
Age, gender, birth order, school attending*, field labour, domestic work, paid work
Health Specific health impairment (disability, chronic disease), hospitalisation in the past year, illness in the past 
3 months (symptoms, healthcare utilisation and expenditures)
HBV vaccination 
and risk factors
HBV vaccination records (HBV-specific birth dose, and pentavalent doses), place of birth, mode of delivery, 
support during delivery, medical history (surgery, blood transfusion, dental care, wounds, stitchesstitches, 
infusion therapy, syringe), scarification, tattoos, piercing (ear, nose, other), acupuncture or assimilated, 
sharing of hygienic equipment (toothbrush, razor, hair needles, manicure and pedicure equipment), 
consumption of prechewed food, circumcision (age, circumstances)†
*Only for children above 5 years old.
†Male children only.
HBV, hepatitis B virus.
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Secondary outcomes
Secondary outcomes include prevalence of chronic HBV 
infection in different subgroups, including adults aged 
15–49 years, women of childbearing age (15–49) and 
age groups 0–15, 15–35 and >35 years. Behavioural and 
environmental risk factors of HBV acquisition in chil-
dren will be explored through data on circumstances of 
birth and circumcision (male children), history of inva-
sive medical care, scarification, tattoos, piercing, sharing 
habits regarding hygienic equipment and consumption of 
prechewed food. The acceptability and uptake of home-
based HBV testing and first clinic visit will be assessed 
with the proportion of participants (i) who agree to be 
tested for HBV among those eligible, (ii) who know their 
HBV status (ie, came to the local healthcare facility to 
receive their results) among those who have been tested 
and (iii) HBsAg-positive participants who accept the first 
step of HBV care—that is, assessment of the disease stage 
through additional biological and clinical examinations, 
including venous blood sampling.
Consequences of chronic HBV infection on living 
conditions of individuals and/or households affected 
by the disease will be investigated using several health 
and socioeconomic outcomes including liver disease 
stage, HBV-related morbidity and mortality (for health 
outcomes) and health-related quality of life, economic 
situation, productivity, income loss and food security (for 
socioeconomic outcomes). In addition, treatment needs 
will be estimated in chronic HBV carriers according to 
the WHO criteria.12 Finally, public health and economic 
impacts of chronic HBV infection will be estimated at the 
population level using the number of quality-adjusted 
life years and costs assessed from the society perspective 
(ie, including indirect costs related to productivity and 
income loss) in the absence of HBV treatment versus in 
different scenarios of access to HBV testing and treatment.
statistical analysis plan
Descriptive analysis of the study population
Description of the overall participation will include the 
participation rate and the comparison of the main socio-
demographic characteristics of the participants with 
that of the whole population living in the Niakhar area 
to identify potential selection bias. In case of significant 
differences, weighting and calibration procedures will be 
used to ensure the representativeness of the study sample. 
The study population will be described in terms of socio-
demographic and economic characteristics of the house-
holds and individuals, overall as well as by gender and age 
groups (<15; 15–35 and >35 years). Missing values higher 
than 10% will be accounted for with multiple imputation 
methods or Heckman type model.61
Table 4 Household (‘kitchen’) questionnaire (head of the household or next of kin)
Main theme Specific themes
General information Number of households in the concession, number of people in the household (adults, children), 
individual questionnaires completed
Agricultural production Agricultural activity, land status, household participation, non-family labour, millet (area cultivated, 
last harvest, sales, current granary stock), peanuts (area cultivated, last harvest, sales), niebe (last 
harvest, sales), bissap (last harvest, sales), other crops (last harvest, sales), draught animals, farm 
equipment
Livestock Feeder animals (possession and sales of fowl, small stock and cattle)
Other sources of income Money from relatives in Senegal or abroad (frequency, amount), government family grant 
(application, outcome, date of the first payment, amount of the last payment)
Food security New millet, food assistance, loan and grant received and given
Household characteristics Consumption goods (inventory and rental income), shop, water supply, power supply (lighting, 
cooking)
Type of housing Occupancy status, number of rooms, rooms for rent (amount, rental income), characteristics of the 
main room (roof, walls, floor)
Table 5 Clinical questionnaire
Main theme Specific themes
Clinical examination Weight, height, blood pressure, body temperature, body mass index, assessment of hepatitis or 
liver disease symptoms
Medical and family history Diagnosed infections, recent hospitalisation, past or ongoing hepatitis treatment, family medical 
history (HCC and cirrhosis) and ongoing treatments
Risk factors of liver disease 
evolution*
Alcohol consumption and tobacco use, sexual behaviour, history of imprisonment
*Only for participants born before 1 September 2003.
HCC, hepatocellular carcinoma. 
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Epidemiology of chronic HBV infection
Estimation of prevalence of chronic HBV infection in 
the whole population and in the different subgroups will 
be computed as the ratio of the number of chronic HBV 
infections over the corresponding population size and 
their respective 95% CIs will be reported. HBV antibodies 
(anti-HBs and anti-HBc) will be described to measure 
the proportion of participants (i) with vaccination-in-
duced immunity (negative HBsAg, negative anti-HBc and 
positive anti-HBs; only in children), (ii) with cured HBV 
infection (negative HBsAg and positive anti-HBc and 
positive anti-HBs) and (iii) susceptible (negative HBsAg, 
negative anti-HBc and negative anti-HBs), respectively. 
Behavioural and environmental factors associated with 
HBV infection in children will be analysed using case-con-
trol (1–3) in multilevel regression models accounting for 
potential households’ effects.
Acceptability of home-based HBV testing and first clinic visit
Acceptability of home-based HBV testing will be esti-
mated through its uptake—that is, the proportion of 
participants who accepted to be tested at home for HBV 
among all those eligible for the study. The acceptability 
assessment will also take into account participation at the 
local healthcare facilities level including the proportion 
of participants that come to get their results, the propor-
tion of chronic HBV carriers who participate in the addi-
tional clinical and biological data collection, as well as 
the subproportion of those participants who come back 
for evaluation of their treatment eligibility. Factors asso-
ciated with the acceptability of home-based HBV testing 
and first clinic visit will also be explored at each of the 
previous steps in multivariate analysis.
Consequences of chronic HBV infection on living conditions at 
individual and household level
Liver disease stage, HBV-related morbidity and treat-
ment needs will be described in chronic HBV carriers 
using biological and clinical data collected in healthcare 
facilities. HBV-related mortality will be estimated in the 
participating households using the ratio of the number 
of individuals whose cause of death was identified as 
chronic liver diseases at year n (using mortality data from 
the Niakhar demographic system) over the average corre-
sponding population at year n. Furthermore, economic 
characteristics (agricultural production, poverty, food 
insecurity) of the households affected by chronic HBV 
infection, including current advanced liver disease in at 
least one household member and recent HBV-related 
mortality (health shock), will be compared with those of 
unaffected households. Individual socioeconomic char-
acteristics (economic situation, productivity, income, 
quality of life) will be compared between those chron-
ically infected and those non-chronically infected. These 
comparisons will identify direct effects of the health 
shocks such as decrease in household earnings, as well as 
intrahousehold coping strategies, including substitution 
effects in terms of labour market participation.
Public health and economic impacts of chronic HBV infection at the 
population level
Building on previous studies,32–34 40 HBV-related 
morbidity and mortality and HBV treatment needs will 
be estimated for the whole population of the Niakhar 
area, as well as for the whole country. The model param-
eters will be defined based on the epidemiological data 
produced by the AmBASS study completed by a litera-
ture review for non-available data. At a given time t, we 
will consider the following three main groups of individ-
uals in the population of the area/country depending 
on HBV infection status: ongoing chronic infection, 
past infection or vaccination-induced immunity and 
uninfected susceptible individuals. Once HBV infected, 
individuals can either spontaneously clear the virus or 
develop chronic hepatitis B infection that can evolve 
towards liver fibrosis stages 1–4, cirrhosis and liver cancer 
potentially leading to death, with different probabilities 
of transitioning from one state to another depending 
on whether people receive treatment or not. We will 
estimate both the public health and economic impacts 
of several hypotheses on HBV testing and treatment 
coverage (varying from 0% corresponding to the absence 
of treatment to 80%). Estimation of treatment needs will 
take into account the probability to be diagnosed as a 
chronic HBV carrier, and the probability to follow each 
of the steps in the HBV treatment and care cascade. Two 
main scenarios of treatment financing will be consid-
ered. In the first scenario, individuals will cover all the 
costs associated with HBV care (including transport, 
treatment and examinations). In the second scenario, a 
third party—which could be the national government or 
an international donor—will finance a variable share of 
total costs (subsidies ranging from 0% to 100%). These 
scenarios will be used to estimate the total cost of HBV 
care and associated health benefits as well as the finan-
cial contributions of the different parties (populations, 
national government or international assistance), given 
the number of people that access care.
All analyses will be performed using the SAS V.9.4 for 
Windows and Stata Stata/SE V.12.1 for Windows.
Patient and public involvement
Patients are not involved in the development of the 
research questions, the design, recruitment or imple-
mentation of this study. Healthcare professionals, public 
health leaders and representatives of the patients associ-
ation contributed to the design of the study through a 
preparatory workshop organised in Dakar in May 2015. 
They also participated in the implementation of the study 
as members of the steering committee. Results will be 
disseminated to patients using posters displayed in all 
three local healthcare facilities involved in the delivery 
of test results. Results will be presented to the patients 
association, healthcare professionals and public health 
leaders during a workshop in Dakar.
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EtHICs And dIssEMInAtIon
Ethical considerations
This study respects the ethical principles defined in the 
current revised version of the Helsinki Declaration (64th 
World Medical Association’s annual Assembly in Fortaleza, 
Brazil–October 2013). The sponsor and the research 
teams are committed to conduct this project in compli-
ance with the applicable national and international regu-
lations on ethics and research involving humans currently 
in force in Senegal and in France. 
Information, consent and data confidentiality
All participants enrolled in the study sign two copies 
of the informed consent form before undertaking any 
examination associated with the study, and after the 
trained interviewer explained the objectives, the nature, 
and the foreseeable constraints and risks of the study. 
A study-specific anonymous identification number is 
assigned to each participant, which ensures correspon-
dence between all data sources (consent form, home-
based questionnaire, medical information form and 
biological samples). Face-to-face questionnaires are 
administered using electronic tablets for immediate 
data input. All data sent to the research teams are anon-
ymous, and the research teams undertaking analyses will 
not have access to nominative data. At the end of the 
study, all study documents (including case report, and 
information and consent forms) will be stored at the 
VITROME-IRD facilities in Dakar for 15 years after the 
end of the study.
Expected benefits and risks for survey participants
The main risk for participants is to learn their HBV status 
following home-based screening, which may have psycho-
logical repercussions given the chronic nature of infec-
tion and the necessity of lifelong antiviral treatments. In 
contrast, the expected benefits of participation in the 
survey include access to information and counselling on 
hepatitis B and access to care for chronic HBV carriers. 
The study participants diagnosed with chronic HBV infec-
tion will benefit from a comprehensive medical examina-
tion and biological check-up to assess the stage of their 
liver disease and treatment eligibility. They will then be 
referred to the Fatick regional hospital for appropriate 
follow-up and care in accordance with the national and 
international guidelines.12 Access to HBV treatment will 
be possible via the National Viral Hepatitis Programme 
once decentralisation is effective, with the first year of 
treatment covered by the study in the meantime. Preg-
nant women with chronic HBV infection, HBeAg posi-
tive and with HBV viral load above 200 000 UI/mL will 
be prescribed tenofovir from the last trimester of gesta-
tion until postpartum week 4,62 paid for by the study. 
Following the National Viral Hepatitis Programme guide-
lines, individuals diagnosed with advanced liver disease 
will be referred to hospitals in Dakar.
Expected results and dissemination plan
The survey results will help fill the lack of epidemiological 
data on chronic HBV infection in the general population 
in rural Senegal. Results of the AmBASS survey will give 
a snapshot of the burden and impacts of hepatitis B in a 
rural area of Senegal, and provide stakeholders with an 
estimation of HBV treatment needs and the economic 
feasibility of expanding access to HBV treatment. The 
reinforcement of local capacities using caregivers 
training and information/education of the local commu-
nities are also among the study’s expected results. Those 
results will be presented during a workshop in Dakar 
to local community leaders and HCW involved in the 
research as well as key stakeholders of the fight against 
HBV in Senegal, including the Saafara patients associa-
tion, members of the SOSEGH, members of the National 
Hepatitis Programme, members of the Ministry of Health 
and Social Action, and members of the Senegalese ethical 
committee (CNERS). They will also be published in inter-
national journals and presented in international confer-
ences to help document treatment needs, and fuel the 
advocacy for decentralised access to HBV care in Senegal.
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